Organisation paid for research Program year 2025 Source: CMS Open Payments

Johnson County Clintrials

Neither a doctor nor a teaching hospital

Research payments

$6,240,036

1,261 payments

Through program year 2025, Johnson County Clintrials is reported as receiving $6,240,036 in research payments, across 1,261 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$373,049	23
2024	Research	$297,375	42
2023	Research	$4,358,262	113
2022	Research	$25,491	2
2021	Research	$125,506	30
2020	Research	$70,417	235
2019	Research	$989,936	816

Breakdown

Who paid Research payments · program years 2019–2025

GlaxoSmithKline, LLC. $3,013,602 52 payments
BioNTech SE $1,069,360 65 payments
Emergent BioSolutions Inc. $885,437 1,048 payments
Novavax Inc $751,956 39 payments
Regeneron Pharmaceuticals, Inc. $248,000 4 payments
Moderna TX, Inc. $193,351 17 payments
Takeda Pharmaceuticals U.S.A., Inc. $74,845 31 payments
Pfizer Inc. $3,485 5 payments

Studies the money was for Research payments · program years 2019–2025

A Protocol to Collect Human Complement (Either Through Collection of S $1,783,055 11 payments
Pre-commercial $918,480 35 payments
VELOCITY: An Anthrax Vaccine Clinical Study $812,353 1,047 payments
A Phase 1/2, Observer-Blind, Randomized, Placebo Controlled Multi-Coun $401,577 15 payments
Phase Iiib, Observer-Blind, Randomized, Placebo-Controlled, Multi-Cent $382,850 4 payments
A Phase I/II Observer-Blind, Randomized, Multi-Center Trial to Evaluat $262,754 14 payments
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, And Pharmacodynamics of Single and Multiple Doses of REGN4461 in Healthy Subjects $248,000 4 payments
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 $194,995 14 payments
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) $171,393 11 payments
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) $155,072 11 payments

What the money was spent on Research payments · program years 2019–2025

Patient care $918,480 35 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.